by McDermott + Bull | Jan 21, 2023 | Insight Into Interim Leaders, Interim Leaders, Mark McConnell, Mark McConnell Article, Video
On this episode of Insight Into Interim Leaders, host Mark McConnell, Sr. Managing Director of McDermott + Bull Interim Leaders, talks more about the types of roles they fill. What Roles Does M+B Interim Leaders Fill? We fill C-level roles across all corporate...
by McDermott + Bull | Jan 13, 2023 | Insight Into Interim Leaders, Interim Leaders, Mark McConnell, Mark McConnell Article, Video
On this episode of Insight Into Interim Leaders, host Mark McConnell, M+B Interim Leaders Senior Managing Director, speaks to why companies utilize their services. Why Do Companies Need M+B Interim Leaders? There are many reasons why companies utilize interim...
by McDermott + Bull | Jan 11, 2023 | Investor Insights, Ken Dropiewski, Video
McDermott + Bull Partner Ken Dropiewski interviews Gilde Healthcare General Partner Geoff Pardo in his series, Investor Insights in Life Sciences + MedTech. In the conversations below, Ken and Geoff discuss what venture in MedTech will look like in 2023, what Gilde...
by McDermott + Bull | Dec 23, 2022 | Insight Into Interim Leaders, Interim Leaders, Julie Francis, Julie Francis Article, Video
On this episode of Insight Into Interim Leaders, McDermott + Bull Interim Leaders Business Development Director Julie Francis, shares how they help during process and operational challenges. How Can Interim Leaders Help Process + Operational Challenges? Another reason...
by McDermott + Bull | Nov 16, 2022 | Investor Insights, Ken Dropiewski, Video
McDermott + Bull Partner Ken Dropiewski interviews Endeavour Venture Partner Rob Barmann in his series, Investor Insights in Life Sciences + MedTech. In the conversations below, Ken and Rob discuss a range of topics from typical investment sizes to non-traditional...
by McDermott + Bull | Aug 26, 2022 | Investor Insights, Ken Dropiewski, Video
McDermott + Bull Partner Ken Dropiewski interviews CRG Director Sabir Rassiwalla in his series, Investor Insights in Life Sciences + MedTech. In the conversations below, Ken and Sabir discuss MedTech’s continuously changing landscape, what makes CRG different...
